Poolbeg Pharma has received notification from the European Patent Office of its decision to grant the company’s Immunomodulator II patent application. The claims cover POLB 001 for the treatment of severe influenza, with Poolbeg continuing to expand its patent portfolio covering POLB 001. In our view, the construction of this patent estate, together with the latest patent approval, should further enhance the value of POLB 001 in the eyes of potential strategic partners.